{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:18:27Z","timestamp":1792225107725,"version":"4.4.0"},"reference-count":93,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["International Reviews of Immunology"],"published-print":{"date-parts":[[2026,7,4]]},"DOI":"10.1080\/08830185.2026.2650139","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:38:31Z","timestamp":1777289911000},"page":"213-228","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Immunoregulation by DC and T cells in psoriasis with probable immunotherapeutic approaches"],"prefix":"10.1080","volume":"45","author":[{"given":"Sharmistha","family":"Kundu","sequence":"first","affiliation":[{"name":"PG Department of Zoology, Barasat Government College","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Paul","sequence":"additional","affiliation":[{"name":"PG Department of Zoology, Barasat Government College","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-6193","authenticated-orcid":false,"given":"Kaustav","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"PG Department of Zoology, Barasat Government College","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/503821"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2467"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12478"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701213"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.194"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.003"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17587"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32127-4"},{"key":"e_1_3_3_16_1","first-page":"1585","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin\u201323 monoclonal antibody, compared with adalimumab for the treatment of moderate to severe psoriasis: results from the phase 3 VOYAGE 2 trial","volume":"376","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et\u00a0al. Efficacy and safety of guselkumab, an anti\u2013interleukin\u201323 monoclonal antibody, compared with adalimumab for the treatment of moderate to severe psoriasis: results from the phase 3 VOYAGE 2 trial. New Eng J Med. 2017;376:1585\u20131596.","journal-title":"New Eng J Med"},{"key":"e_1_3_3_17_1","first-page":"1546","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"379","author":"Gordon KB","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et\u00a0al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. New Eng J Med. 2018;379:1546\u20131556.","journal-title":"New Eng J Med"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_3_19_1","first-page":"654","article-title":"Therapeutic drug monitoring of biologics in psoriasis","volume":"14","author":"Rodr\u00edguez-Fern\u00e1ndez S","year":"2022","unstructured":"Rodr\u00edguez-Fern\u00e1ndez S, Alonso-Castro L, Bravo B, Abad-Santos F. Therapeutic drug monitoring of biologics in psoriasis. Pharmaceutics. 2022;14:654.","journal-title":"Pharmaceutics"},{"key":"e_1_3_3_20_1","article-title":"Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2","author":"Ellinghaus E","year":"2012","unstructured":"Ellinghaus E, Ellinghaus D, Stuart PE, et\u00a0al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 2012.","journal-title":"Nat Genet"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15382"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546422"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.65"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092385"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100123"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.08.001"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.164"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199616"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103421"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-101011-155833"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01235-5"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14075"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2013"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.08.016"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S397079"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.3.265"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.702264"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2019.0050"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2020.20.02.003"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0357-z"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-009-0703-x"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.499699"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.02.007"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.06.001"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.020206"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202045"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109585"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.05.009"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/363159a0"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577792"},{"key":"e_1_3_3_57_1","first-page":"371","article-title":"Increased nerve growth factor and substance P in psoriasis","volume":"111","author":"Jiang WY","year":"1998","unstructured":"Jiang WY, Raychaudhuri SP, Farber EM. Increased nerve growth factor and substance P in psoriasis. J Invest Dermatol. 1998;111:371\u2013375.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00544.x"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.002"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.11.003"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.52135"},{"issue":"3","key":"e_1_3_3_62_1","first-page":"iii68","article-title":"Substance P receptor-mediated macrophage responses","volume":"60","author":"Marriott I","year":"2001","unstructured":"Marriott I, Bost KL. Substance P receptor-mediated macrophage responses. Ann Rheum Dis. 2001;60(Suppl 3):iii68\u2013iii72.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_3_63_1","first-page":"C865","article-title":"Neuropeptide substance P and the immune system","volume":"311","author":"Mashaghi A","year":"2016","unstructured":"Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune system. Am J Physiol Cell Physiol. 2016;311:C865\u2013C879.","journal-title":"Am J Physiol Cell Physiol"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153864"},{"key":"e_1_3_3_65_1","first-page":"448","article-title":"Substance P activates NF-\u03baB in murine macrophages","volume":"165","author":"Marriott I","year":"2000","unstructured":"Marriott I, Mason MJ, Elhofy A, Bost KL. Substance P activates NF-\u03baB in murine macrophages. J Immunol. 2000;165:448\u2013452.","journal-title":"J Immunol"},{"key":"e_1_3_3_66_1","first-page":"428","article-title":"Substance P-immunoreactive nerves in psoriasis","volume":"281","author":"Naukkarinen A","year":"1989","unstructured":"Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Substance P-immunoreactive nerves in psoriasis. Arch Dermatol Res. 1989;281:428\u2013433.","journal-title":"Arch Dermatol Res"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-007-0745-x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70208-b"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02385-3"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158578"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14071"},{"key":"e_1_3_3_72_1","first-page":"219","article-title":"Vasoactive intestinal peptide: A neuropeptide with pleiotropic immune functions","volume":"27","author":"Delgado M","year":"2004","unstructured":"Delgado M, Ganea D. Vasoactive intestinal peptide: A neuropeptide with pleiotropic immune functions. Amino Acids. 2004;27:219\u2013229.","journal-title":"Amino Acids"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348097"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1366.004"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.06.002"},{"key":"e_1_3_3_76_1","first-page":"1342","article-title":"Vasoactive intestinal peptide induces vascular endothelial growth factor production in human keratinocytes","volume":"117","author":"Kakurai M","year":"2001","unstructured":"Kakurai M, Fujita N, Murata T, Furue M. Vasoactive intestinal peptide induces vascular endothelial growth factor production in human keratinocytes. J Invest Dermatol. 2001;117:1342\u20131347.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_3_77_1","unstructured":"Gordon KB Langley RG Leonardi C et\u00a0al. Efficacy of etanercept in patients with psoriasis. New Eng J Med. 2006;355:2295\u20132307."},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_3_3_79_1","first-page":"529","article-title":"Golimumab in the treatment of immune-mediated diseases with cutaneous involvement: a review of the literature","volume":"8","author":"Tsianakas A","year":"2018","unstructured":"Tsianakas A, Papadavid E. Golimumab in the treatment of immune-mediated diseases with cutaneous involvement: a review of the literature. Dermatol Ther (Heidelb). 2018;8:529\u2013542.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_3_3_80_1","first-page":"960","article-title":"Efficacy and safety of certolizumab pegol in patients with moderate-to-severe chronic plaque psoriasis: 48-week results from two randomized phase 3 studies (CIMPASI-1 and CIMPASI-2)","volume":"81","author":"Reich K","year":"2019","unstructured":"Reich K, Puig L, Mallbris L, Zhang H, Osuntokun OO, Hao Y. Efficacy and safety of certolizumab pegol in patients with moderate-to-severe chronic plaque psoriasis: 48-week results from two randomized phase 3 studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2019;81:960\u2013969.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017"},{"key":"e_1_3_3_83_1","first-page":"541","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"358","author":"Leonardi CL","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et\u00a0al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). New Eng J Med. 2008;358:541\u2013551.","journal-title":"New Eng J Med"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094681"},{"key":"e_1_3_3_86_1","first-page":"95","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"342","author":"Schafer PH","year":"2012","unstructured":"Schafer PH, Parton A, Capone L, et\u00a0al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. J Pharmacol Exp Ther. 2012;342:95\u2013104.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_3_87_1","unstructured":"Assay Genie. 2025. Fezakinumab: Exploring its mechanism and clinical potential."},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13568-025-01931-4"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.016"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae035"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10195.x"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key173"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010497.pub2"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4"}],"container-title":["International Reviews of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08830185.2026.2650139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/08830185.2026.2650139","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08830185.2026.2650139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:18:43Z","timestamp":1782746323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08830185.2026.2650139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,4]]}},"alternative-id":["10.1080\/08830185.2026.2650139"],"URL":"https:\/\/doi.org\/10.1080\/08830185.2026.2650139","relation":{},"ISSN":["0883-0185","1563-5244"],"issn-type":[{"value":"0883-0185","type":"print"},{"value":"1563-5244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iiri20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iiri20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}